Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADVIL LIQUI-GELS vs ACULAR LS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.
Mild to moderate pain,Primary dysmenorrhea,Osteoarthritis,Rheumatoid arthritis,Fever reduction,Migraine (off-label)
FDA: Treatment of postoperative inflammation in patients who have undergone cataract surgery,Off-label: Relief of ocular pain, photophobia, and inflammation associated with corneal abrasion or refractive surgery
200–400 mg orally every 4–6 hours as needed; maximum 1200 mg/day.
1 drop in the affected eye(s) four times daily
1.8 to 2.5 hours. The short half-life supports dosing every 4 to 6 hours for acute pain and fever.
The terminal elimination half-life is approximately 1.8 hours (range 1.2–2.5 hours) following topical ocular administration. This short half-life is consistent with rapid clearance from the systemic circulation.
Primarily hepatic via CYP2C9, with minor pathways including glucuronidation and CYP2C8. Metabolites are inactive.
Primarily hepatic via CYP2C9; undergoes glucuronidation and oxidation to inactive metabolites.
Renal excretion of metabolites and conjugates accounts for approximately 90% of an administered dose. Less than 1% is excreted unchanged. Biliary/fecal elimination accounts for about 10%.
Renal excretion of metabolites and unchanged drug accounts for approximately 26% of the dose. Fecal excretion accounts for approximately 74% of the dose, primarily as metabolites.
Approximately 99% bound to albumin.
Ketorolac is highly protein bound, approximately 99% bound to plasma proteins, primarily albumin.
0.1 to 0.2 L/kg. Low Vd reflects extensive protein binding and limited tissue distribution.
The volume of distribution is approximately 0.12 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral bioavailability of ibuprofen from Liqui-Gels is approximately 85-90% due to first-pass metabolism.
Ophthalmic bioavailability is approximately 2% of the administered dose due to extensive nasolacrimal drainage and systemic absorption. Oral bioavailability of ketorolac is approximately 80-100%, but this route is not used for ophthalmic formulations.
e GFR 30–59 m L/min: maximum 800 mg/day in divided doses. e GFR <30 m L/min: contraindicated.
No dosage adjustment required for renal impairment
Child-Pugh Class A: no adjustment. Class B: reduce dose by 50% and monitor. Class C: avoid use.
No dosage adjustment required for hepatic impairment but use with caution in severe hepatic disease due to potential for increased systemic exposure
Children ≥12 years: 200 mg orally every 4–6 hours, max 800 mg/day. Children <12 years: use weight-based ibuprofen (5–10 mg/kg/dose, max 40 mg/kg/day) not with Liqui-Gels formulation.
Safety and efficacy in pediatric patients below 2 years of age have not been established; for children 2 years and older, same as adult dosing
Start at lowest effective dose; maximum 800 mg/day due to increased risk of GI and renal adverse effects.
No specific dose adjustment recommended; use with caution due to increased incidence of age-related ocular conditions
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
None
Increased risk of gastrointestinal adverse events including bleeding, ulceration, and perforation; use lowest effective dose for shortest duration; avoid in patients with advanced renal disease; may cause hypertension or worsening of pre-existing hypertension; caution in patients with asthma, coagulation disorders, or fluid retention.
Increased risk of bleeding and bleeding-related adverse events due to platelet inhibition,May prolong bleeding time,Cross-sensitivity with aspirin and other NSAIDs,Caution in patients with prior history of corneal epithelial defects or ocular surgery,Not for intraocular injection
Hypersensitivity to ibuprofen or any component; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in CABG surgery; history of gastrointestinal bleeding or perforation related to NSAIDs; severe heart failure.
Hypersensitivity to ketorolac tromethamine or any component of the formulation,Patients with active peptic ulcer disease, recent GI bleeding, or perforation,Patients with advanced renal disease or at risk for renal failure,Patients with known history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
Alcohol increases risk of GI bleeding. No specific food restrictions; however, taking with high-fat meals may delay absorption but reduces GI irritation.
No known food interactions for ophthalmic ketorolac. However, maintain good hydration and nutrition to support corneal healing.
First trimester: NSAIDs are associated with increased risk of miscarriage and cardiac defects. Second trimester: Generally considered safer; however, avoid prolonged use. Third trimester: Avoid due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal impairment.
Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during organogenesis resulted in increased embryofetal mortality, delayed ossification, and increased incidence of skeletal abnormalities at doses less than the maximum recommended human ophthalmic dose. However, systemic exposure following ocular administration is very low. NSAIDs are generally avoided during pregnancy, especially in the third trimester, due to the risk of premature closure of the ductus arteriosus and oligohydramnios. The risk is considered low for ophthalmic use but should be used only if clearly needed.
Ibuprofen is excreted in breast milk in low concentrations (M/P ratio approximately 0.01). Considered compatible with breastfeeding by the AAP. Use lowest effective dose for shortest duration.
It is not known whether ketorolac is excreted in human milk after ophthalmic administration. Systemic levels are low, and following oral administration, ketorolac is excreted in breast milk at low concentrations (M/P ratio approximately 0.37). Due to the potential for adverse effects on the nursing infant, caution should be exercised. The low systemic absorption likely poses minimal risk.
No specific dose adjustment required based on pharmacokinetic changes. Use lowest effective dose for shortest duration. Avoid in third trimester.
No dosing adjustments are necessary for ophthalmic use during pregnancy due to negligible systemic absorption. Standard dosing (1 drop in the affected eye(s) four times daily) is recommended. Systemic NSAIDs may require dose adjustment due to increased volume of distribution and renal changes, but this does not apply to topical ocular ketorolac.
Advil Liqui-Gels contain solubilized ibuprofen, allowing for faster absorption (onset ~20-30 min) compared to solid tablets. The liquid-filled gel capsule may cause more gastrointestinal distress in sensitive patients; administer with food. Avoid in patients with severe heart failure, history of GI bleed, or after coronary artery bypass grafting. Monitor renal function in elderly or dehydrated patients. Use lowest effective dose for shortest duration.
ACULAR LS (ketorolac tromethamine ophthalmic solution 0.4%) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the reduction of ocular pain and photophobia following corneal refractive surgery. Use with caution in patients with known bleeding tendencies or those on anticoagulants due to increased risk of ocular bleeding. Avoid concurrent use with other NSAIDs or steroids to minimize corneal adverse effects. Monitor for corneal epithelial breakdown or delayed healing.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg per day unless directed by a doctor.,Swallow whole; do not crush, chew, or break the capsule.,Avoid alcohol while taking this medication.,Stop and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (e.g., black/tarry stools).,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Do not take with other NSAIDs (e.g., aspirin, naproxen).
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 10 minutes before reinserting.,Use only in the affected eye(s) as prescribed; do not use for longer than directed.,Temporary stinging or burning may occur upon instillation.,Report any persistent pain, redness, or visual changes to your doctor immediately.,Avoid driving or operating machinery if vision is blurred after use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADVIL LIQUI-GELS vs ACULAR LS, answered by our medical review team.
ADVIL LIQUI-GELS is a NSAID that works by Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.. ACULAR LS is a NSAID Ophthalmic that works by Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADVIL LIQUI-GELS and ACULAR LS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADVIL LIQUI-GELS is: 200–400 mg orally every 4–6 hours as needed; maximum 1200 mg/day.. The standard adult dose of ACULAR LS is: 1 drop in the affected eye(s) four times daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADVIL LIQUI-GELS and ACULAR LS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADVIL LIQUI-GELS is classified as Category C. First trimester: NSAIDs are associated with increased risk of miscarriage and cardiac defects. Second trimester: Generally considered safer; however, avoid prolonged use. Third tri. ACULAR LS is classified as Category C. Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during org. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.